<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01048905</url>
  </required_header>
  <id_info>
    <org_study_id>1R01FD003531-01</org_study_id>
    <secondary_id>IRB 2008-059</secondary_id>
    <nct_id>NCT01048905</nct_id>
  </id_info>
  <brief_title>Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension</brief_title>
  <official_title>Phase 2 Trial for Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital &amp; Research Center Oakland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital &amp; Research Center Oakland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary hypothesis of this study is that glutamine supplementation will improve the
      erythrocyte glutamine/glutamate ratio, a biomarker of oxidative stress, hemolysis and
      pulmonary hypertension (PH) in sickle cell disease (SCD) and thalassemia (Thal) patients with
      PH. PH is defined as a tricuspid regurgitant jet velocity (TRV) on Doppler echocardiography &gt;
      2.5 m/s. We also predict that glutamine therapy will increase arginine bioavailability and
      subsequently alter sickle red cell endothelial interaction that can be identified using
      endo-PAT technology through nitric oxide (NO) generation, leading to changes in biological
      markers, and clinical outcome. Specifically our second hypothesis is that oral glutamine will
      decrease biomarkers of hemolysis and adhesion molecules, and improve the imbalanced
      arginine-to-ornithine ratio that occurs in hemolytic anemias, leading to improved arginine
      bioavailability and clinical endpoints of endothelial dysfunction and PH in patients with SCD
      and Thal.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in erythrocyte glutamine/glutamate ratio, a novel biomarker of oxidative stress,post therapy compared to pre-therapy steady-state values.</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Glutamine</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tricuspid Regurgitant Jet velocity on Doppler Echocardiography</measure>
    <time_frame>8 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6 minute walk distance</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function tests</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function tests</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <condition>Sickle Cell Disease</condition>
  <condition>Thalassemia</condition>
  <arm_group>
    <arm_group_label>Pharmacokinetics</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 hour pharmacokinetics after glutamine supplementation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive an 8-week course of oral L-glutamine 10 grams TID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-Glutamine</intervention_name>
    <description>Oral L-glutamine 10 grams TID or (0.1g/kg TID) for children &lt; 15 years of age.</description>
    <arm_group_label>Pharmacokinetics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-Glutamine</intervention_name>
    <description>Oral L-glutamine 10 grams TID or (0.1g/kg TID) for children &lt; 15 years of age.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established diagnosis of SCD (Hb SS, SC or SBeta- thalassemia) or Thal

          -  PH documented by echocardiography, defined as at TRV greater than 2.5 m/s

          -  Age greater than or equal to 4 years

        Exclusion Criteria:

          -  Inability to take or tolerate oral medication

          -  Acute crisis or hospitalization within 1 month of enrollment

          -  Hepatic dysfunction (SGPT greater than 3X normal)

          -  Renal dysfunction (Creatinine greater than 2X normal)

          -  Allergy to glutamine

          -  Pregnancy or breastfeeding

          -  Patients on sildenafil (Viagra), calcium channel blockers, or amino acid/protein
             supplements (other therapies acceptable if stable more than 3 months)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudia Morris, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Augusta Saulys, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hosptial &amp; Research Center Oakland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital &amp; Research Center Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2010</study_first_submitted>
  <study_first_submitted_qc>January 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2010</study_first_posted>
  <last_update_submitted>July 17, 2014</last_update_submitted>
  <last_update_submitted_qc>July 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Hypertension</keyword>
  <keyword>Sickle Cell Disease</keyword>
  <keyword>Thalassemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

